Plus Therapeutics Inc. held a Special Meeting of Stockholders on May 2, 2025. Stockholders approved a Certificate of Amendment to increase the authorized shares of common stock from 100,000,000 to 2,000,000,000. Discretionary authority was granted to the Board to conduct a reverse stock split at a ratio between one-for-twenty-five and one-for-two-hundred-fifty, to be executed within twelve months. Additionally, stockholders authorized the issuance of shares in compliance with Nasdaq Listing Rule 5635(d).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-062742), on May 02, 2025, and is solely responsible for the information contained therein.